Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price (USD) | Volume |
|---|---|---|---|
| 2021-11-18 | American Depositary Shares (ADSs) | $41.5000 | 2,626.374 (Dr. Barron) |
| 2021-11-18 | American Depositary Shares (ADSs) | $41.5000 | 65 (Dr. Barron) |
| 2021-11-18 | American Depositary Shares (ADSs) | $41.5000 | 62.798 (Mr. Ford) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It details routine acquisitions of ADSs by executives via dividend reinvestment plans.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this specific filing. The transactions were executed on the New York Stock Exchange (XNYS) and were classified as initial notifications.
Investor Verification Points
- Transaction Nature: Verify that all reported acquisitions were automatic reinvestments of dividends within executive savings plans (Executive Supplemental Savings Plan and 401(k) plan), not open-market purchases.
- Executive Involvement: Confirm the identities of the PDMRs involved: Dr. H Barron (Chief Scientific Officer and President, R&D) and Mr. J Ford (SVP & General Counsel).
- Share Price Consistency: Note that all transactions occurred at a uniform price of $41.50 per ADS on November 18, 2021.
- Instrument Type: Ensure the transactions relate to American Depositary Shares (ISIN: US37733W1053) rather than ordinary shares.